- Home
- CIO vs LCTX Comparison
CIO vs LCTX Comparison
Compare CIO & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIO
- LCTX
- Stock Information
- Founded
- CIO 2013
- LCTX 1990
- Country
- CIO Canada
- LCTX United States
- Employees
- CIO N/A
- LCTX N/A
- Industry
- CIO Real Estate Investment Trusts
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIO Real Estate
- LCTX Health Care
- Exchange
- CIO Nasdaq
- LCTX Nasdaq
- Market Cap
- CIO 280.5M
- LCTX 274.0M
- IPO Year
- CIO 2014
- LCTX N/A
- Fundamental
- Price
- CIO $7.01
- LCTX $1.67
- Analyst Decision
- CIO Hold
- LCTX Strong Buy
- Analyst Count
- CIO 1
- LCTX 4
- Target Price
- CIO N/A
- LCTX $4.25
- AVG Volume (30 Days)
- CIO 548.8K
- LCTX 1.7M
- Earning Date
- CIO 10-30-2025
- LCTX 11-13-2025
- Dividend Yield
- CIO 5.72%
- LCTX N/A
- EPS Growth
- CIO N/A
- LCTX N/A
- EPS
- CIO N/A
- LCTX N/A
- Revenue
- CIO $168,892,000.00
- LCTX $10,914,000.00
- Revenue This Year
- CIO $0.60
- LCTX N/A
- Revenue Next Year
- CIO $3.53
- LCTX $176.00
- P/E Ratio
- CIO N/A
- LCTX N/A
- Revenue Growth
- CIO N/A
- LCTX 76.43
- 52 Week Low
- CIO $4.19
- LCTX $0.37
- 52 Week High
- CIO $7.01
- LCTX $1.80
- Technical
- Relative Strength Index (RSI)
- CIO 74.58
- LCTX 64.50
- Support Level
- CIO $6.93
- LCTX $1.66
- Resistance Level
- CIO $6.97
- LCTX $1.80
- Average True Range (ATR)
- CIO 0.02
- LCTX 0.12
- MACD
- CIO -0.01
- LCTX 0.01
- Stochastic Oscillator
- CIO 93.75
- LCTX 72.92
About CIO City Office REIT Inc.
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.